Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Rectal Cancer: early-phase trial registry
A small indexed set (9 trials) with no open enrollment listed right now.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · none currently recruiting · #1,916 of 28,707 conditions by registered trial count
Recurrent Rectal Cancer: 9 US clinical trials tracked, none currently recruiting.
Recurrent Rectal Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-rectal-cancer
OPEN 0 | RECR 0% | LATE 0 | EARLY 9 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Rectal Cancer has no open enrollment in this registry pull (9 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Rectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Rectal Cancer is recruiting below its size-band peers.
0 of 9 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Rectal Cancer research.
National Cancer Institute (NCI) accounts for 4 of 9 trials (44.4%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Rectal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 19 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Recurrent Rectal Cancer research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
9 total, page 1 of 1
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT00077298
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
National Cancer Institute (NCI)
NCT00138177
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT01105377
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
NCT01821105
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT02232152
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
City of Hope Medical Center
NCT00645710
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
John Hays
NCT01814501
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT00023933
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
City of Hope Medical Center
NCT01191684
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Rectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Rectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Rectal Cancer page
9 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Rectal Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Recurrent Rectal Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Rectal Cancer condition card totals 9 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.